Influenza Vaccine Market by Vaccine Type (Inactivated, Live Attenuated, Recombinant), Age Group (Adult, Geriatric, Pediatric), Dosage, Presentation, Distribution Channel, End User - Global Forecast 2025-2032
Description
The Influenza Vaccine Market was valued at USD 8.61 billion in 2024 and is projected to grow to USD 9.41 billion in 2025, with a CAGR of 9.60%, reaching USD 17.94 billion by 2032.
A strategic orientation to the contemporary influenza vaccine environment integrating clinical advances, supply chain realities, regulatory dynamics, and stakeholder objectives
Influenza vaccination remains a cornerstone of public health strategy, with ongoing innovation reshaping how prevention is conceptualized, produced, and delivered. Recent advances in antigen design, adjuvant formulation, and delivery systems have converged with heightened expectations for seasonal and pandemic preparedness, prompting stakeholders across clinical, manufacturing, and distribution domains to reassess priorities. As a result, decision makers are navigating a more complex interplay of scientific opportunity, regulatory scrutiny, and supply chain resilience than in prior seasons.
Consequently, this executive summary frames the contemporary influenza vaccine environment through the dual lenses of clinical performance and operational feasibility. It emphasizes the need for alignment among manufacturers, health systems, and procurement agencies to ensure timely availability and appropriate matching of vaccine formats to population needs. By synthesizing technological advances with operational realities, the introduction establishes the context for the subsequent sections, which explore transformative shifts, tariff implications, segmentation nuances, regional differentials, competitive behavior, and practical recommendations for leaders aiming to secure both public health and commercial objectives.
Defining the next era of influenza vaccine delivery through platform innovation, improved presentation formats, data-driven deployment, and resilient supply chain strategies
The influenza vaccine landscape is undergoing transformative shifts driven by technological maturation, policy recalibration, and evolving stakeholder expectations. The emergence of alternative platforms such as recombinant and cell-based antigen production has reduced reliance on egg-based processes, enabling faster scale-up and potentially broader strain coverage. Parallel improvements in delivery systems, notably the increasing use of prefilled syringes in glass and plastic formats and refined vial presentations, are simplifying administration workflows and reducing wastage in clinical settings. These technical changes are reinforced by a growing emphasis on improved formulations for older adults and high-risk populations, which in turn affect product positioning and procurement strategies.
Beyond core manufacturing innovations, the sector is seeing advances in data-driven immunization planning and surveillance that inform strain selection and deployment timing. Policymakers and healthcare providers are placing greater emphasis on equitable access and programmatic resilience, which is catalyzing investment in diversified manufacturing footprints and stronger public-private collaboration. At the same time, vaccine confidence and outreach strategies are adapting to a more fragmented media environment, requiring integrated communications and community-level engagement to maintain uptake. Taken together, these shifts are redefining competitive advantage and creating new imperatives for agility across R&D, supply chain management, and commercial execution.
Assessing how 2025 United States tariff measures alter supply chain economics, sourcing strategies, packaging availability, and procurement risk for influenza vaccine stakeholders
Recent tariff actions in the United States have introduced an added layer of complexity to influenza vaccine logistics and sourcing decisions. Increased duties on imported components, packaging materials, and specialized devices can compress margins for manufacturers that rely on global supply chains for raw materials and prefilled syringe components. In response, procurement teams and manufacturers are reassessing supplier contracts, considering nearshoring of critical inputs, and evaluating the cost-benefit trade-offs of sourcing alternatives that may impose higher unit costs but improve supply security.
These dynamics have direct operational implications for both single-dose and multi-dose presentations, as well as for glass and plastic syringe supply chains. Facilities that depend on imported stoppers, plungers, or specific vial assemblies may face longer lead times and variability in availability, prompting contingency planning and greater inventory buffers. Regulatory compliance also becomes more prominent, since manufacturing adjustments to domesticize inputs can require validation and sometimes additional filings with oversight agencies. Ultimately, tariffs influence not only procurement economics but also strategic decisions about where to invest in capacity, how to structure long-term supplier partnerships, and how to align commercial pricing strategies with public health obligations.
Deep segmentation insights across vaccine types, patient cohorts, dosage formats, presentation variants, distribution channels, and end-user configurations to guide tailored strategies
Key segmentation insights emerge when the market is analyzed across established categorical frameworks. Based on Vaccine Type, market is studied across Inactivated, Live Attenuated, and Recombinant, and each category carries distinct implications for manufacturing lead times, cold chain requirements, and target population messaging. Based on Age Group, market is studied across Adult, Geriatric, and Pediatric, which requires differentiated formulation strategies, dosing schedules, and clinical outreach tailored to immune response profiles and comorbidity patterns. Based on Dosage, market is studied across Multi Dose and Single Dose, and this distinction affects inventory management, wastage rates, and the economics of distribution to rural or high-volume clinics. Based on Presentation, market is studied across Prefilled Syringe and Vial; the Prefilled Syringe is further studied across Glass Prefilled Syringe and Plastic Prefilled Syringe, while the Vial is further studied across Multi Dose Vial and Single Dose Vial, all of which influence administration speed, safety perceptions, and waste handling practices within health systems.
Based on Distribution Channel, market is studied across Direct Sales and Hospital Pharmacies, with implications for contract negotiation, rebate structures, and visibility into real-world utilization. Based on End User, market is studied across Clinics and Hospitals; the Clinics segment is further studied across Outpatient Clinics and Specialty Clinics, while the Hospitals segment is further studied across Private Hospitals and Public Hospitals, each of which has different procurement cycles, budget constraints, and cold chain capabilities. Together, these segmentation lenses highlight where product design, packaging, and commercial approaches must be finely tuned to match the operational realities and clinical needs of disparate stakeholders.
Comparative regional intelligence across the Americas, Europe Middle East & Africa, and Asia-Pacific that explains regulatory, infrastructure, and procurement differentials
Regional dynamics shape demand drivers, regulatory approaches, and distribution imperatives across three broad territories. In the Americas, immunization programs are influenced by well-established seasonal vaccination campaigns, advanced cold chain infrastructure in many markets, and a mix of public procurement and private pay models that drive varied access and pricing strategies. Transitional policies and public health investment decisions in certain subnational jurisdictions can materially affect uptake and logistics planning, prompting suppliers to align distribution and contracting with both federal and state-level procurement cycles.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist alongside significant variation in healthcare infrastructure and financing. In some markets, centralized procurement and strong public immunization programs support high coverage among priority groups, while in others limited cold chain capacity and constrained budgets necessitate adaptable presentation formats such as single-dose vials or prefills. Asia-Pacific displays a similarly diverse set of conditions, ranging from high-volume national immunization initiatives with advanced manufacturing capabilities to emerging markets that prioritize cost-effective presentations and stronger local production partnerships. Across all regions, regulatory expectations, logistics constraints, and public health priorities should inform tailored approaches to presentation selection, supply commitments, and stakeholder engagement.
How leading manufacturers and suppliers are aligning platform innovation, fill-finish integration, and channel strategies to secure supply and clinical credibility
Leading companies in the influenza vaccine domain are differentiating through technology investment, manufacturing agility, and strategic partnerships. Some firms are accelerating work on recombinant and cell-based platforms to reduce dependence on legacy egg-based production and to shorten timelines for strain updates. Others are focusing on presentation innovations such as prefilled syringes in both glass and plastic formats to improve administration efficiency and reduce medication errors in high-volume settings. Contract manufacturing organizations and device suppliers are also extending their capabilities to support more complex fill-finish workflows, which has shifted the competitive landscape toward integrated solutions that combine antigen supply, fill-finish, and delivery device expertise.
Commercially, organizations are refining channel strategies by strengthening direct sales to institutional buyers while maintaining relationships with hospital pharmacies that manage bulk distribution and cold chain logistics. Strategic alliances with public health agencies and multi-year supply agreements have become important levers to secure demand visibility and justify capital investments. At the same time, firms are investing in real-world evidence generation and post-marketing surveillance to demonstrate broader effectiveness and support positioning for higher-risk cohorts. Collectively, these corporate moves underscore a pragmatic focus on aligning R&D trajectories with manufacturability and end-user convenience.
Actionable, priority-focused recommendations for manufacturers, distributors, and health system leaders to enhance resilience, adoption, and operational efficiency
Industry leaders should prioritize a set of pragmatic actions to navigate the evolving influenza vaccine environment. First, diversify sourcing for critical inputs and consider nearshoring or dual-sourcing strategies to reduce tariff exposure and mitigate supplier concentration risk. Second, accelerate investment in platforms and formulations that reduce dependence on constrained inputs and support more rapid strain updates, while ensuring regulatory pathways are pre-mapped. Third, align product presentation choices-single-dose versus multi-dose and glass versus plastic prefilled syringes-with end-user capabilities and waste-management infrastructure to optimize uptake and minimize programmatic friction.
Moreover, strengthen relationships with hospital pharmacies and direct institutional purchasers through transparent contracting and shared forecasting to improve supply visibility. Enhance engagement with public health stakeholders to co-design outreach that addresses vaccine confidence and access barriers. Invest in surveillance and real-world evidence generation to support targeted dosing strategies for geriatric and pediatric cohorts. Finally, incorporate scenario planning into procurement and capacity investments to ensure agility in the face of tariff shifts, geopolitical events, or sudden demand surges, thereby protecting both public health objectives and commercial viability.
A transparent, mixed-methods research approach combining secondary synthesis and primary stakeholder interviews to validate operational and clinical insights
The research methodology underpinning this executive summary combined systematic secondary research with targeted primary engagements to ensure a robust evidence base. Secondary sources included regulatory guidance documents, peer-reviewed literature on influenza immunology and vaccine technologies, manufacturing best-practice materials, and publicly available procurement policy announcements. These sources were synthesized to establish baseline facts about platform characteristics, presentation formats, and distribution modalities.
Primary research was conducted through structured interviews with immunization program leaders, procurement specialists, clinical vaccinators, and manufacturing experts to capture operational constraints and practical trade-offs in real-world settings. Supply chain mapping and presentation-specific workflows were validated with device suppliers and hospital pharmacy managers to understand fill-finish implications and cold chain requirements. Cross-validation steps included triangulating interview insights with published safety and efficacy data and with regulatory submissions where publicly available. Throughout, the methodology emphasized transparency in assumptions, reproducibility of analytic steps, and sensitivity to regional heterogeneity so that findings remain actionable for a wide range of stakeholders.
Concluding synthesis that connects clinical innovation, distribution pragmatics, and procurement resilience to actionable priorities for influenza vaccine stakeholders
In conclusion, the influenza vaccine landscape is simultaneously dynamic and decision-critical: technological innovation offers meaningful opportunities to improve effectiveness and administration, while supply chain and policy shifts introduce concrete operational risks. Success in this environment will depend on the ability of manufacturers, distributors, and health systems to synchronize product design, presentation choice, and procurement strategies with real-world delivery capabilities. Diversification of supply chains, careful selection of presentation formats tailored to end-user needs, and investment in evidence generation are central to reducing programmatic friction and maintaining public trust.
Looking ahead, those organizations that proactively address tariff exposure, align channel strategies with hospital and clinic workflows, and invest in platforms that enable faster and more flexible manufacturing will be best positioned to meet clinical and public health objectives. By integrating clinical, operational, and commercial planning, stakeholders can enhance resilience and better serve diverse populations across regional and institutional contexts.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic orientation to the contemporary influenza vaccine environment integrating clinical advances, supply chain realities, regulatory dynamics, and stakeholder objectives
Influenza vaccination remains a cornerstone of public health strategy, with ongoing innovation reshaping how prevention is conceptualized, produced, and delivered. Recent advances in antigen design, adjuvant formulation, and delivery systems have converged with heightened expectations for seasonal and pandemic preparedness, prompting stakeholders across clinical, manufacturing, and distribution domains to reassess priorities. As a result, decision makers are navigating a more complex interplay of scientific opportunity, regulatory scrutiny, and supply chain resilience than in prior seasons.
Consequently, this executive summary frames the contemporary influenza vaccine environment through the dual lenses of clinical performance and operational feasibility. It emphasizes the need for alignment among manufacturers, health systems, and procurement agencies to ensure timely availability and appropriate matching of vaccine formats to population needs. By synthesizing technological advances with operational realities, the introduction establishes the context for the subsequent sections, which explore transformative shifts, tariff implications, segmentation nuances, regional differentials, competitive behavior, and practical recommendations for leaders aiming to secure both public health and commercial objectives.
Defining the next era of influenza vaccine delivery through platform innovation, improved presentation formats, data-driven deployment, and resilient supply chain strategies
The influenza vaccine landscape is undergoing transformative shifts driven by technological maturation, policy recalibration, and evolving stakeholder expectations. The emergence of alternative platforms such as recombinant and cell-based antigen production has reduced reliance on egg-based processes, enabling faster scale-up and potentially broader strain coverage. Parallel improvements in delivery systems, notably the increasing use of prefilled syringes in glass and plastic formats and refined vial presentations, are simplifying administration workflows and reducing wastage in clinical settings. These technical changes are reinforced by a growing emphasis on improved formulations for older adults and high-risk populations, which in turn affect product positioning and procurement strategies.
Beyond core manufacturing innovations, the sector is seeing advances in data-driven immunization planning and surveillance that inform strain selection and deployment timing. Policymakers and healthcare providers are placing greater emphasis on equitable access and programmatic resilience, which is catalyzing investment in diversified manufacturing footprints and stronger public-private collaboration. At the same time, vaccine confidence and outreach strategies are adapting to a more fragmented media environment, requiring integrated communications and community-level engagement to maintain uptake. Taken together, these shifts are redefining competitive advantage and creating new imperatives for agility across R&D, supply chain management, and commercial execution.
Assessing how 2025 United States tariff measures alter supply chain economics, sourcing strategies, packaging availability, and procurement risk for influenza vaccine stakeholders
Recent tariff actions in the United States have introduced an added layer of complexity to influenza vaccine logistics and sourcing decisions. Increased duties on imported components, packaging materials, and specialized devices can compress margins for manufacturers that rely on global supply chains for raw materials and prefilled syringe components. In response, procurement teams and manufacturers are reassessing supplier contracts, considering nearshoring of critical inputs, and evaluating the cost-benefit trade-offs of sourcing alternatives that may impose higher unit costs but improve supply security.
These dynamics have direct operational implications for both single-dose and multi-dose presentations, as well as for glass and plastic syringe supply chains. Facilities that depend on imported stoppers, plungers, or specific vial assemblies may face longer lead times and variability in availability, prompting contingency planning and greater inventory buffers. Regulatory compliance also becomes more prominent, since manufacturing adjustments to domesticize inputs can require validation and sometimes additional filings with oversight agencies. Ultimately, tariffs influence not only procurement economics but also strategic decisions about where to invest in capacity, how to structure long-term supplier partnerships, and how to align commercial pricing strategies with public health obligations.
Deep segmentation insights across vaccine types, patient cohorts, dosage formats, presentation variants, distribution channels, and end-user configurations to guide tailored strategies
Key segmentation insights emerge when the market is analyzed across established categorical frameworks. Based on Vaccine Type, market is studied across Inactivated, Live Attenuated, and Recombinant, and each category carries distinct implications for manufacturing lead times, cold chain requirements, and target population messaging. Based on Age Group, market is studied across Adult, Geriatric, and Pediatric, which requires differentiated formulation strategies, dosing schedules, and clinical outreach tailored to immune response profiles and comorbidity patterns. Based on Dosage, market is studied across Multi Dose and Single Dose, and this distinction affects inventory management, wastage rates, and the economics of distribution to rural or high-volume clinics. Based on Presentation, market is studied across Prefilled Syringe and Vial; the Prefilled Syringe is further studied across Glass Prefilled Syringe and Plastic Prefilled Syringe, while the Vial is further studied across Multi Dose Vial and Single Dose Vial, all of which influence administration speed, safety perceptions, and waste handling practices within health systems.
Based on Distribution Channel, market is studied across Direct Sales and Hospital Pharmacies, with implications for contract negotiation, rebate structures, and visibility into real-world utilization. Based on End User, market is studied across Clinics and Hospitals; the Clinics segment is further studied across Outpatient Clinics and Specialty Clinics, while the Hospitals segment is further studied across Private Hospitals and Public Hospitals, each of which has different procurement cycles, budget constraints, and cold chain capabilities. Together, these segmentation lenses highlight where product design, packaging, and commercial approaches must be finely tuned to match the operational realities and clinical needs of disparate stakeholders.
Comparative regional intelligence across the Americas, Europe Middle East & Africa, and Asia-Pacific that explains regulatory, infrastructure, and procurement differentials
Regional dynamics shape demand drivers, regulatory approaches, and distribution imperatives across three broad territories. In the Americas, immunization programs are influenced by well-established seasonal vaccination campaigns, advanced cold chain infrastructure in many markets, and a mix of public procurement and private pay models that drive varied access and pricing strategies. Transitional policies and public health investment decisions in certain subnational jurisdictions can materially affect uptake and logistics planning, prompting suppliers to align distribution and contracting with both federal and state-level procurement cycles.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist alongside significant variation in healthcare infrastructure and financing. In some markets, centralized procurement and strong public immunization programs support high coverage among priority groups, while in others limited cold chain capacity and constrained budgets necessitate adaptable presentation formats such as single-dose vials or prefills. Asia-Pacific displays a similarly diverse set of conditions, ranging from high-volume national immunization initiatives with advanced manufacturing capabilities to emerging markets that prioritize cost-effective presentations and stronger local production partnerships. Across all regions, regulatory expectations, logistics constraints, and public health priorities should inform tailored approaches to presentation selection, supply commitments, and stakeholder engagement.
How leading manufacturers and suppliers are aligning platform innovation, fill-finish integration, and channel strategies to secure supply and clinical credibility
Leading companies in the influenza vaccine domain are differentiating through technology investment, manufacturing agility, and strategic partnerships. Some firms are accelerating work on recombinant and cell-based platforms to reduce dependence on legacy egg-based production and to shorten timelines for strain updates. Others are focusing on presentation innovations such as prefilled syringes in both glass and plastic formats to improve administration efficiency and reduce medication errors in high-volume settings. Contract manufacturing organizations and device suppliers are also extending their capabilities to support more complex fill-finish workflows, which has shifted the competitive landscape toward integrated solutions that combine antigen supply, fill-finish, and delivery device expertise.
Commercially, organizations are refining channel strategies by strengthening direct sales to institutional buyers while maintaining relationships with hospital pharmacies that manage bulk distribution and cold chain logistics. Strategic alliances with public health agencies and multi-year supply agreements have become important levers to secure demand visibility and justify capital investments. At the same time, firms are investing in real-world evidence generation and post-marketing surveillance to demonstrate broader effectiveness and support positioning for higher-risk cohorts. Collectively, these corporate moves underscore a pragmatic focus on aligning R&D trajectories with manufacturability and end-user convenience.
Actionable, priority-focused recommendations for manufacturers, distributors, and health system leaders to enhance resilience, adoption, and operational efficiency
Industry leaders should prioritize a set of pragmatic actions to navigate the evolving influenza vaccine environment. First, diversify sourcing for critical inputs and consider nearshoring or dual-sourcing strategies to reduce tariff exposure and mitigate supplier concentration risk. Second, accelerate investment in platforms and formulations that reduce dependence on constrained inputs and support more rapid strain updates, while ensuring regulatory pathways are pre-mapped. Third, align product presentation choices-single-dose versus multi-dose and glass versus plastic prefilled syringes-with end-user capabilities and waste-management infrastructure to optimize uptake and minimize programmatic friction.
Moreover, strengthen relationships with hospital pharmacies and direct institutional purchasers through transparent contracting and shared forecasting to improve supply visibility. Enhance engagement with public health stakeholders to co-design outreach that addresses vaccine confidence and access barriers. Invest in surveillance and real-world evidence generation to support targeted dosing strategies for geriatric and pediatric cohorts. Finally, incorporate scenario planning into procurement and capacity investments to ensure agility in the face of tariff shifts, geopolitical events, or sudden demand surges, thereby protecting both public health objectives and commercial viability.
A transparent, mixed-methods research approach combining secondary synthesis and primary stakeholder interviews to validate operational and clinical insights
The research methodology underpinning this executive summary combined systematic secondary research with targeted primary engagements to ensure a robust evidence base. Secondary sources included regulatory guidance documents, peer-reviewed literature on influenza immunology and vaccine technologies, manufacturing best-practice materials, and publicly available procurement policy announcements. These sources were synthesized to establish baseline facts about platform characteristics, presentation formats, and distribution modalities.
Primary research was conducted through structured interviews with immunization program leaders, procurement specialists, clinical vaccinators, and manufacturing experts to capture operational constraints and practical trade-offs in real-world settings. Supply chain mapping and presentation-specific workflows were validated with device suppliers and hospital pharmacy managers to understand fill-finish implications and cold chain requirements. Cross-validation steps included triangulating interview insights with published safety and efficacy data and with regulatory submissions where publicly available. Throughout, the methodology emphasized transparency in assumptions, reproducibility of analytic steps, and sensitivity to regional heterogeneity so that findings remain actionable for a wide range of stakeholders.
Concluding synthesis that connects clinical innovation, distribution pragmatics, and procurement resilience to actionable priorities for influenza vaccine stakeholders
In conclusion, the influenza vaccine landscape is simultaneously dynamic and decision-critical: technological innovation offers meaningful opportunities to improve effectiveness and administration, while supply chain and policy shifts introduce concrete operational risks. Success in this environment will depend on the ability of manufacturers, distributors, and health systems to synchronize product design, presentation choice, and procurement strategies with real-world delivery capabilities. Diversification of supply chains, careful selection of presentation formats tailored to end-user needs, and investment in evidence generation are central to reducing programmatic friction and maintaining public trust.
Looking ahead, those organizations that proactively address tariff exposure, align channel strategies with hospital and clinic workflows, and invest in platforms that enable faster and more flexible manufacturing will be best positioned to meet clinical and public health objectives. By integrating clinical, operational, and commercial planning, stakeholders can enhance resilience and better serve diverse populations across regional and institutional contexts.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expansion of mRNA technology applications in quadrivalent and universal influenza vaccine development
- 5.2. Adoption of high-dose and adjuvanted vaccine formulations for enhanced immunogenicity in elderly populations
- 5.3. Implementation of digital health platforms for real-time influenza vaccine efficacy monitoring and reporting
- 5.4. Regulatory fast-track approvals and emergency use authorizations accelerating novel influenza vaccine candidates
- 5.5. Strategic collaboration between pharmaceutical companies and local manufacturers to address regional vaccine shortages
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Influenza Vaccine Market, by Vaccine Type
- 8.1. Inactivated
- 8.2. Live Attenuated
- 8.3. Recombinant
- 9. Influenza Vaccine Market, by Age Group
- 9.1. Adult
- 9.2. Geriatric
- 9.3. Pediatric
- 10. Influenza Vaccine Market, by Dosage
- 10.1. Multi Dose
- 10.2. Single Dose
- 11. Influenza Vaccine Market, by Presentation
- 11.1. Prefilled Syringe
- 11.1.1. Glass Prefilled Syringe
- 11.1.2. Plastic Prefilled Syringe
- 11.2. Vial
- 11.2.1. Multi Dose Vial
- 11.2.2. Single Dose Vial
- 12. Influenza Vaccine Market, by Distribution Channel
- 12.1. Direct Sales
- 12.2. Hospital Pharmacies
- 13. Influenza Vaccine Market, by End User
- 13.1. Clinics
- 13.1.1. Outpatient Clinics
- 13.1.2. Specialty Clinics
- 13.2. Hospitals
- 13.2.1. Private Hospitals
- 13.2.2. Public Hospitals
- 14. Influenza Vaccine Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Influenza Vaccine Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Influenza Vaccine Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Sanofi S.A.
- 17.3.2. CSL Limited
- 17.3.3. GlaxoSmithKline plc
- 17.3.4. AstraZeneca plc
- 17.3.5. Pfizer Inc.
- 17.3.6. Sinovac Biotech Ltd.
- 17.3.7. China National Pharmaceutical Group Co., Ltd.
- 17.3.8. Serum Institute of India Private Limited
- 17.3.9. Changchun BCH Bioengineering Co., Ltd.
- 17.3.10. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
